Wednesday, 17 Oct 2018

You are here

Statin Associated with an Increase in Inflammatory Myopathy

JAMA Internal Medicine reports that exposure to statin medications may be linked to histologically confirmed idiopathic inflammatory myositis.

A population-based, case-control study, using the South Australian Myositis Database, examined 221 patients with idiopathic inflammatory myositis (IIM) matched 1:3 with 662 controls. The 221 IIM cases had a mean age of 62.2 years, and 132 (59.7%) were female

Statin exposure at the time of IIM diagnosis was seen in 30.8% of the IIM patients  and 21.5% of controls (P = .005). There was a statistically significant 79% increased risk of idiopathic inflammatory myositis cases in those exposed to a statin drug  compared with controls (adjusted odds ratio, 1.79; 95% CI, 1.23-2.60; P = .001). 

The CDC estimates nearly 71% of adults with cardiovascular disease and 54% of adults with hypercholesterolemia use a cholesterol-lowering. While myalgias are common,  but myopathy occurs in less than 1% and rhabdomyolysis and necrotizing myositis are very rare.  A NEJM article has shown that autoantibodies against 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase and is estimated to occur in approximately 2 or 3 of every 100,000 patients treated with statins.  

 

 

 

 

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Teenage Obesity Increases Lupus Risk

Analysis of the Black Women's Health Study shows that obesity as a teenager may be associated with increased risk of systemic lupus erythematous (SLE) in adulthood.

The relationship between obesity and SLE risk is unclear. Past studies have predominantly assessed white women, while black women have higher prevalence of both obesity and SLE.

SLE-Scleroderma Overlap Outcomes

Overlap of autoimmune disorders represents a significant diagnostic and management challenge to the rheumatologist. A novel cohort analysis of overlap between systemic sclerosis (SSc) and systemic lupus erythematous (SLE) suggests such patients tend to be younger, more frequently have PAH, but less cutaneous manifestations of SSc.

Excess Mortality in CTD or Systemic Vasculitis Patients

The Norwegian connective tissue disease (CTD) and systemic vasculitis (PSV) registry (NOSVAR) studied patient outcomes over a 15 year period and found overall mortality to be higher in the CTD compared to the PSV group.

Mortality Improves in Lupus ESRD

The past two decades have seen a significant decline in mortality among patients with lupus nephritis, U.S. registry data indicated.

Ustekinumab May be Effective in Lupus

Ronald F van Vollenhoven and colleagues have reported in Lancet that ustekinumab (UST), an interleukin-12 and -23 inhibitor, when added to usual therapy in systemic lupus erythematosus (SLE) patients, was shown to be superior to placebo at improving clinical efficacy and laboratory parameters after 6 months of therapy.